Please assess the completion status of the following clinical trial:

Trial Title: Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of MDS~* Documented significant cytopenia for at least 2 months~* Adequate liver and kidney function~* Ineligible for stem cell bone marrow transplantation~* At least 18 years of age~* Discontinuation of growth factors (e.g., G-CSF) within 3 weeks of study entry~Exclusion Criteria:~* Prior bone marrow transplant~* Failure to recover from any prior surgery or any major surgery within 4 weeks of study entry~* Pregnant or lactating women~* Other investigational drugs within 14 days of study entry~* Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day

Based on this trial design, predict the completion outcome and termination type (if applicable).